Goldman Sachs
GSK icon

Goldman Sachs’s GSK GSK Stock Holding History

Goldman Sachs’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-602,500
Closed -$21.5M – 5676
2023
Q2 		$21.5M Buy
602,500
+143,500
+31% +$5.15M ﹤0.01% 1782
2023
Q1 		$16.3M Buy
+459,000
New +$16.1M ﹤0.01% 1994
2018
Q4 		– Sell
-2,240
Closed -$112K – 5410
2018
Q3 		$112K Hold
2,240
– – ﹤0.01% 5099
2018
Q2 		$113K Sell
2,240
-1,840
-45% -$92.7K ﹤0.01% 5186
2018
Q1 		$199K Sell
4,080
-12,320
-75% -$574K ﹤0.01% 5006
2017
Q4 		$727K Sell
16,400
-44,480
-73% -$2.05M ﹤0.01% 4544
2017
Q3 		$3.09M Buy
60,880
+32,240
+113% +$1.64M ﹤0.01% 3599
2017
Q2 		$1.54M Buy
28,640
+2,640
+10% +$141K ﹤0.01% 4054
2017
Q1 		$1.37M Sell
26,000
-83,760
-76% -$4.25M ﹤0.01% 4100
2016
Q4 		$5.28M Buy
109,760
+41,600
+61% +$2.05M ﹤0.01% 3006
2016
Q3 		$3.67M Buy
68,160
+3,280
+5% +$180K ﹤0.01% 3312
2016
Q2 		$3.52M Buy
64,880
+18,000
+38% +$948K ﹤0.01% 3152
2016
Q1 		$2.38M Sell
46,880
-42,400
-47% -$2.11M ﹤0.01% 3321
2015
Q4 		$4.5M Buy
89,280
+9,280
+12% +$473K ﹤0.01% 2927
2015
Q3 		$3.85M Buy
80,000
+8,160
+11% +$425K ﹤0.01% 3121
2015
Q2 		$3.74M Buy
71,840
+5,120
+8% +$288K ﹤0.01% 3211
2015
Q1 		$3.85M Buy
66,720
+8,880
+15% +$509K ﹤0.01% 3147
2014
Q4 		$3.09M Sell
57,840
-10,640
-16% -$595K ﹤0.01% 3427
2014
Q3 		$3.94M Sell
68,480
-10,320
-13% -$633K ﹤0.01% 3256
2014
Q2 		$5.27M Sell
78,800
-34,400
-30% -$2.33M ﹤0.01% 2976
2014
Q1 		$7.56M Sell
113,200
-29,440
-21% -$1.99M ﹤0.01% 2612
2013
Q4 		$9.52M Buy
142,640
+49,440
+53% +$3.21M ﹤0.01% 2406
2013
Q3 		$5.84M Sell
93,200
-1,840
-2% -$118K ﹤0.01% 2771
2013
Q2 		$5.94M Buy
+95,040
New +$6.03M ﹤0.01% 2570

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs's GSK Position: Q2 2026 in Review

Goldman Sachs reduced its GSK (GSK) stake by 34% in Q2 2026, selling an estimated $170M and leaving 6,371,442 shares worth $334M. The position accounts for 0.03% of the portfolio, ranked #552.

Goldman Sachs first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $529M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Goldman Sachs held 6,371,442 shares of GSK worth $334M as of Q2 2026.
  • Goldman Sachs sold 3,217,672 GSK shares in Q2 2026, an estimated $170M.
  • GSK made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #552 holding.
  • Goldman Sachs first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's GSK position peaked at $529M in Q1 2026.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.